Press Releases

Dec 02, 2021
BeiGene Announces Inclusion in the China National Reimbursement Drug List (NRDL) of Tislelizumab in Three New Indications, BRUKINSA® (Zanubrutinib) in One New Indication, and the First Listing for Pamiparib    read more...
Dec 02, 2021
BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT® (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease    read more...
Dec 02, 2021
BeiGene to Present New Clinical Data on Tislelizumab at ESMO IO Congress 2021    read more...
Nov 30, 2021
BeiGene Announces Pricing of its RMB22.2 billion (US$3.5 billion) Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China    read more...
Nov 23, 2021
BeiGene Announces Approval of BRUKINSA (zanubrutinib) in the European Union for Treatment of Adults with Waldenström’s Macroglobulinemia    read more...
Nov 23, 2021
BeiGene Launches Proposed Initial Public Offering on the STAR Market in China    read more...
Nov 23, 2021
BeiGene Closes on Property for New U.S. Manufacturing and Clinical R&D Center    read more...
Nov 22, 2021
BeiGene Initiates First-in-Human Phase 1 Clinical Trial of Investigational TYK2 Inhibitor BGB-23339    read more...
Nov 14, 2021
BeiGene and NewBridge Pharmaceuticals Announce Approval in Saudi Arabia of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma    read more...
Nov 04, 2021
BeiGene Reports Third Quarter 2021 Financial Results    read more...
Nov 04, 2021
BeiGene to Present Clinical Data on BRUKINSA in Chronic Lymphocytic Leukemia at the 63rd ASH Annual Meeting    read more...
Oct 20, 2021
BeiGene and Nanolek Announce Approval in Russia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma    read more...
Oct 10, 2021
BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma    read more...
Oct 07, 2021
BeiGene Announces First Regulatory Approval in Australia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Waldenström’s Macroglobulinemia    read more...
Sep 22, 2021
Leap Therapeutics and BeiGene Announce First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer    read more...
Sep 20, 2021
BeiGene Announces Inclusion in FTSE Russell Indices    read more...
Sep 17, 2021
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström’s Macroglobulinemia    read more...
Sep 15, 2021
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma    read more...
Sep 13, 2021
BeiGene Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab in Esophageal Squamous Cell Carcinoma    read more...
Sep 12, 2021
BeiGene to Present Latest Findings in Robust Lung Cancer Portfolio at ESMO Congress 2021    read more...